The RAINIER Study: RAINIER will be a phase 3 registrational, randomized, placebo-controlled study of povetacicept in adults with IgA Nephropathy (IgAN). The drug will be administered once every 4 weeks as a subcutaneous injection. The study is expected to start enrollment in the U.S. in H2 2024. More details will be announced in the coming months (information provided as of May 1, 2024).
